Bristol-Myers ends hepatitis C drug development

(AP)—Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.

The New York company said Thursday that it decided to discontinue development of the drug, labeled BMS-986094, in the interest of .

The patient's prompted Bristol-Myers to voluntarily suspend a mid-stage study of the drug on Aug 1. The U.S. subsequently placed the drug on a clinical hold.

"The decision to halt development of BMS-986094 has been guided by our overriding interest in protecting patients," Elliott Sigal, Bristol-Myers' chief scientific officer, said in a statement.

Nine patients, including the one who died, were hospitalized. Two remain under hospital care, the company said.

Bristol-Myers said it hasn't definitively established what caused patients to become ill, but identified heart and kidney toxicity as a key factor.

The company said it is working with the FDA to monitor the patients involved in the study. It also said it would continue to investigate the potential cause of the drug's toxicity.

can prove fatal to experimental drugs. The FDA has been focusing more on those risks since & Co. took its painkiller Vioxx off the market several years ago after a study showed the drug doubled the risk of heart attack or stroke.

Bristol Myers has been pushing to become a player in the drug market, which is expected to grow as baby boomers get older.

The discontinued drug was one of two main potential hepatitis C treatments from Bristol-Myers that investors are focused on. The other is a compound labeled daclatasvir that has started late-stage testing, the last step before drugmakers submit a product to regulators for approval.

Bristol-Myers acquired BMS-986094 and some other potential treatments as part of a $2.5 billion acquisition of drug developer Inhibitex Inc. it completed earlier this year.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts say the market for treatments is potentially lucrative for drugmakers. More people are expected to be diagnosed with the tough-to-treat disease as the baby boomer generation ages.

After a two-decade drought, the first two new hepatitis C drugs were approved last year: Victrelis from Merck & Co. and Incivek from Vertex Pharmaceuticals Inc. and Johnson & Johnson. Both significantly improve the cure rate over what has long been the standard of care, a mix of injections and pills with nasty, flu-like side effects that takes several months and still doesn't cure many patients.

' shares tumbled when it first announced earlier this month that it was suspending its trial of the C drug. In aftermarket trading Thursday, they added 5 cents to $32.20. The stock ended the regular trading session up 34 cents at $32.15.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Vaccine proves effective against deadly Middle East virus

21 hours ago

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

22 hours ago

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments